OncoMatch/Clinical Trials/NCT06429150
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Is NCT06429150 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CAR-T cells for multiple myeloma.
Treatment: CAR-T cells — The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Demographics
Prior therapy
Must have received: autologous stem cell transplant
After prior auto-SCT is eligible regardless of other prior therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06429150 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received autologous stem cell transplant.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages